- Tissue Engineering Journal Club
Interested in Clean Meat? Human Organs for Transplant? Health and Medicine? Show up for our monthly Tissue Engineering Journal Club where we visit cutting edge research and pre-published research in the field and discuss pressing issues and hurdles around tapping into this bioengineering revolution.
- IndieBio: Female Founders "The Journey Talks"
Females Only: Please RSVP on the Eventbrite https://www.eventbrite.com/e/indiebio-female-founders-the-journey-talks-tickets-62542388969 Joining us on the panel in a discussion about "Power": Lucy Caldwell is a social psychologist, venture philanthropist and creator of the Life Revealed podcast featuring the defining stories of trailblazers of the world. For twenty years she has devoted herself to the science and practice of how people change, drawing upon the traditions of social psychology and wisdom based practices. Lucy is a steward of aligning people to their highest purpose and truth with an emphasis on awakening, empowering and dynamically reshaping culture. Julia Li led the marketing team at Scalable Press - the world’s first tech company using software and automation to disrupt the $30B printing industry. Scalable Press is unfunded and profitable, with over 300 employees and over 25 million products shipped. Li is an accidential, serial entrepreneur. At 21, she founded Agency Element - a brand management firm that drove over $500M in revenue and averaged 350% return for clients. Their work spanned across multiple verticals including luxury goods, lifestyle/consumer services, B2B markets, and the hospitality industry. Li is the former CMO of Materialist, a venture-backed startup solving the massive material sourcing challenge for the $235B interior building materials market. She later built a funded, stealth-mode beauty subscription startup before joining Scalable Press. Dr. Helen Chen, Founder of Guided Clarity. Guided Clarity has developed a new class of compounds to target and clear cells of dysfunctional mitochondria, improving cellular energy production. Their compounds are synthesized from naturally-occurring ingredients in food, so they are both safe and affordable as a medical food. In their first clinical study on healthy volunteers, the data showed an increase in insulin sensitivity, a reduction in inflammation marker NLR, and improved physical function. Guided Clarity is focused on healthy aging, improving mitochondrial function both in the brain and on the periphery. Dr. Siv Watkins, Founder of 11Biomics. 11Biomics has developed a very effective, non-pesticide plant treatment that solves a huge problem for the fast-growing cannabis industry — powdery mildew disease. Powdery mildew disease can spike in a cannabis grow operation overnight, ruining a harvest worth millions. Existing antifungal treatments are ineffective or damage the plant. 11Biomics heals plants in a manner of hours by rebalancing the plant’s phytobiome, using natural hyper-antagonists to fungal diseases. Their platform of seven plant therapeutics allows 11Biomics to tune their therapy to different regions of the country, as well as treat other crops commonly affected by powdery mildew — hops, grapes, and tomatoes. Dr. Inja Radman, Founder of New Culture Foods. New Culture is making cheese without the cow. Combining dairy proteins, expressed by microflora, with plant lipids and sugars, their method arrives at curds that are then advanced into the traditional cheesemaking process, be that stirred, kneaded, stretched or aged. New Culture’s cheese has the signature textural properties and qualities that we’re all familiar with in dairy cheese. By removing the cow from the cheesemaking process, New Culture’s cheese is more sustainable, ethical, and better for the world.
- MedGenome Immune profiling applications symposium
*** RSVP on Eventbrite: https://www.eventbrite.com/e/medgenome-immune-profiling-applications-symposium-tickets-61940796590 *** Please join us for an exciting line of speakers for MedGenome's June 4th symposium on Genomics & Immune profiling applications. Dinner will be served at the event. Speaker : Sarah Taylor, PhD, Staff Scientist, 10x Genomics Title : High Resolution Profiling of the Antigen-Specific T Cell Response Speaker : Mark White, PhD, Sr. Director, Scientific Affairs at Berkeley Lights, Inc. Title: Stuck on function? Analyze the function of individual T cells in 1 day Speaker : Rikhia Chakraborty, PhD, Assistant Professor, Texas Childrens' Hospital Title : Terrible T’s in LCH Sampathkumar Rangasamy, PhD Assistant Professor, TGEN Title : Importance of disease phenotype in rare and complex disorders
- Future of Therapeutics & Diagnostics
*** RSVP on Eventbrite: https://www.eventbrite.com/e/future-of-therapeutics-diagnostics-tickets-61910409702 *** Cancer, antibiotic-resistant infections, immune disorders, microbiome disorders, and aging are looming health treats to everyone. How can we use biotech and computation to outsmart these diseases? Come hear from five startups that are working on the next generation of therapeutics and diagnostics. Light snacks and drinks served. Speakers: Helen Chen, CEO of Guided Clarity (gclarity.com) Guided Clarity has developed a new class of compounds to target and clear cells of dysfunctional mitochondria, improving cellular energy production. Their compounds are synthesized from naturally-occurring ingredients in food, so they are both safe and affordable as a medical food. In their first clinical study on healthy volunteers, the data showed an increase in insulin sensitivity, a reduction in inflammation marker NLR, and improved physical function. Guided Clarity is focused on healthy aging, improving mitochondrial function both in the brain and on the periphery. Michael Wyman, CEO of Beeline Therapeutics (beelinetherapeutics.com) Beeline turns your body’s own cells into drug factories to express antibodies, enzymes, or cytokines. Their method facilitates localized drug expression. They replace expensive therapeutic protein regimens that have to be injected weekly or monthly. They’re working to reprogram a patient’s immune cells to suppress inflammation and autoimmune disease, effectively curing patients for many years. Kevin Honaker, CEO of BiomeSense (biomesenseinc.com) The microbiome is one of the most impactful emerging fields in healthcare, yet fundamentally constrained by a lack of biomarkers to measure treatment efficacy. BiomeSense’s platform is a 30x reduction in the cost of doing longitudinal microbiome collection and analysis research, unlocking this exploding market. Their single-chip, on-toilet design will prep and assay the microbiome strains and upload the data to their cloud. BiomeSense is quickly signing pilot partners to use their device in clinical trials, as well as securing LOIs with partners who desire access to their unique, centralized data. Franco Goytia, CEO of Caspr Bio (http://caspr.bio) Caspr is a diagnostics company that uses CRISPR for rapid detection of antimicrobial resistance. Today, when a patient has an infection, it takes three days to determine which bacterial strains are proliferating. Physicians are desperate to know, faster, if a patient has the resistant superbug KPC, or bacteria with the resistant-gene NDM-1. Caspr Bio is making an affordable, point-of-care device that can make this diagnosis in two hours. They use CRISPR to identify the DNA of the most dangerous infectious strains. They will be extending this platform to upgrade many diagnostics with CRISPR. Marcel Frenkel, Co-founder of Gavilan Biodesign (gavilanbio.com) Gavilan Biodesign is an in silico computational design company that redesigns drugs for pharma companies, so cancers cannot develop resistance to the drug. Cancer cells mutate rapidly and comes back after most therapeutic treatments. Currently, pharma companies design drugs to target a specific, likely mutation. But then a new mutation makes the cancer resistant to that drug, too. Gavilan is a unique computational drug design company with capabilities new to this field. Their physics-based engine models all possible mutations around a binding site to predict which set of mutations will successfully emerge. Then they redesign a drug to remain effective, not just against one or two mutations, but against all possible future mutations. They can search through 100 trillion molecular structures a day, arriving at superior drug compound structures in a matter of hours. Their goal is to work with many pharma partners to create a new class of targeted therapies that dramatically extend progression-free survival.
- Design Jam: Accelerating Science Through Technology
To attend this event, please RSVP on Eventbrite: https://www.eventbrite.com/e/design-jam-accelerating-science-through-technology-tickets-61662506216 Join us in Downtown Berkeley for a Design Jam: Accelerating Science Through Technology. What is a Design Jam? A Design Jam is a mini-hackathon where a challenge/prompt is presented in the beginning of the event. The challenge will be related to solving problems related to the advancement of science. Attendees will be getting in groups of 5-6 and will have one hour to come up with an innovative solution to this problem. Accelerating Science Through Technology With the digital information age, we are given many opportunities to access information. Scientific and technology advances in communication and the way we share knowledge is growing fast. This event will allow attendees to focus on these shifts in industry. This event will be hosting designers, scientists, and anyone interested in science and technology. No prior experience required, all are welcome! To attend this event, please RSVP on Eventbrite: https://www.eventbrite.com/e/design-jam-accelerating-science-through-technology-tickets-61662506216
- [cross-post] Putting CRISPR-Cas9 into context
*** Original post: https://www.meetup.com/SF-Synthetic-Biology/events/260964475/ *** Hello Synbiologists! Our next meetup is planned for Tuesday May 28 and I look forward to seeing you there. Collin Edington has graciously offered to walk us through his knowledge of CRISPR. Should be fun! The talk will provide an accessible overview of how CRISPR-Cas technology works, its discovery, uses, and potential applications. Other gene editing techniques will also be covered to give better context to why CRISPR has made such a dramatic impact in the synthetic biology community. We'll once again have pizza wine & beer sponsored by Shasta Ventures (thank you!) and time to get to know each other. 5:30pm Arrival and refreshments 6pm Members introductions and interests 6:30pm Presentation 6:50pm Q&A 7pm wrap-up Shasta Ventures is generously hosting us at their SF office for this event. Collin Edington is currently Head of Lab Technologies and Operations at Culture Biosciences, where he is working to design and build stirred tank bioreactors from the ground up for automation and efficiency. Culture Bio operates these reactors as a cloud service for the synthetic biology community, enabling scalable R&D capacity to increase speed to market for biological products. Before coming to Culture, Collin received his PhD in bioengineering from the University of Pittsburgh, then spent his post-doc at MIT designing human organ-on-a-chip devices to emulate multi-organ systems, enabling researchers to better simulate complex diseases and drug interactions in-vitro. Thanks to Collin for being willing to share his knowledge with us!
- Networking Event for Petcare Industry
Join local pet care startups and national industry leaders for an evening of exploring what's going on in the Bay Area and how the startups here can grow with investment and corporate relationships. The pet care industry is a $75B industry in just the United States, and startups are making a major impact. The Pet Care Innovation Prize is a program that gives cash and valuable business support to up to five innovative pet care companies per year - without the startups giving up any rights or equity. Light snacks and beverages will be served. Active Capital and 9-Square Ventures present the Pet Care Innovation Prize, powered by Purina.
- D2HACK Challenge: Global Innovation in Early Life Medtech and Healthcare
From allergen detection, tracking digestion and nutrition, to microbiome identification and more, staying in the know about early life are ever-crucial to the growth and development of a child. The application of digital innovation is key in improving the efficiency and efficacy of healthcare, and associated insights for further research and development - but what are the real market demands of these technologies and how do they differ internationally? Did you know, Singapore is home to 9% of all health tech startups in Asia Pacific, just behind China and India? In 2018, the government announced that it will invest US$13 billion over 5 years, in research and development, of which part of it will go to health care innovation. Besides startups, many multi-national companies have also set up global or regional innovation teams in Singapore to develop new health care solutions. Join us to learn more about the latest research and technologies that can change our lives, how Danone's global research team in Singapore works with startups and scientists to develop groundbreaking solutions, and how you can be part of this exciting journey by participating in D2Hack Challenge! About D2Hack: At Danone Nutricia Research - Precision Nutrition Digital Lab of Singapore, we are excited to find partners who would embark with us in the journey of bringing health to people through digital innovation, with a particular focus on early life. We are calling for all international startups or teams of technologists who may have relevant skills or solutions to take part to the first D2Hack: the Danone Digitalization Hackathon. Learn more about the solutions we are looking for here: http://d2hackchallenge.com/ Speakers: Reshmi Rajendran, Director of Precision Nutrition D-Lab, Danone Nutricia (Early Life Nutrition) Pavan Kumar, Co-founder, Cocoon Cam Jun Axup, Scientific Director & Partner, IndieBio Chaeyoung Shin, Co-founder & CEO, Sugarlogix Christina Hsiang, Founder, Startups Greater Asia Timeline: 6.30pm: Registration and Dinner 7.00pm: Panel Discussion on biotech innovations in nutrition and health care 7.30pm: Danone’s Showcase of the D2Hack Challenge + Q&A 8.00pm: Networking Session ----- Brought to you by: Danone Nutricia Research and NUS Enterprise About Danone Nutricia Research: Danone Nutricia Research is a global research and innovation organization behind Early Life Nutrition and Specialized Nutrition. We bring health through food to as many people as possible, particularly those who need special care. Science is at the heart of our nutrition and health commitment. Therefore, we focus our skills and resources to deliver specialized nutrition to mothers and infants, patients, and the elderly. About NUS Enterprise: NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS), plays a pivotal role in advancing innovation and entrepreneurship at NUS and beyond. It actively promotes entrepreneurship and cultivates global mind-sets and talents through the synergies of experiential entrepreneurial education, active industry partnerships, holistic entrepreneurship support and catalytic entrepreneurship outreach. Its initiatives and global connections support a range of entrepreneurial journeys and foster ecosystem building in new markets. These initiatives augment and complement the University’s academic programmes and act as a unique bridge to industry well beyond Singapore’s shores.
- How Biotechnology is Saving the Planet
*** RSVP on Eventbrite: https://www.eventbrite.com/e/how-biotechnology-is-saving-the-planet-tickets-60435848249 *** Climate change, pollution, and food sustainability are increasingly becoming a global problem. But as we only have one Earth (for now), we must push for innovations in planetary health. Biology as a technology is well-suited for solving problems at the planetary scale as it naturally grows and feeds into a circular economy. Come hear how startups are using biology to create renewable energy, decrease plastics and dye processing waste, and feed the planet with healthy protein. Food and drinks provided. Speakers: Michelle Zhu, CEO of Tinctorium (tinctoriumbio.com) Tinctorium is making the greenest bluejeans for the planet, using biofermentation in their indigo dye process. Across the $100 billion jeans market today, the vast majority of blue denim relies on chemical synthesis and chemical reduction, which significantly harms both the environment and the health of denim workers. Even naturally-grown, plant indigo is reduced with corrosive chemicals. Tinctorium is unique among denim producers, as their system is both scalable and free of chemical synthesis and reduction. Alex Lewis, CEO of Electro-Active Technologies (electroactive.tech) Around the world, biomass is inefficiently converted to biogas or syngas, then to useable electricity. A more efficient approach is to convert liquid biomass and food waste straight to hydrogen for fuel cells. The founders of ElectroActive developed this bioconversion technology at the Oak Ridge National Laboratory in Tennessee. Their modular power cubes will be used in any quantity to provide renewable power anywhere food waste or biomass is prevalent. Electro-Active is a scalable solution that serves many industrial supply chains, especially in municipalities that have banned food waste from landfills. Paul Schmitzberger, CEO of Blue Planet Ecosystems (blue-planet-ecosystems.com) Blue Planet develops modular systems that turn sunlight into fish — at an industrial scale. A Blue Planet Ecosystem is a closed-loop stack of six shipping-containers; the system continuously self-optimizes as algae grows on the sunlight, zooplankton grows on the algae, and high-value commercial fish grows on the zooplankton. Thermal energy management and marine life conversion efficiency is handled by their software. In locations where land is cheap and sunlight is plentiful, dozens or hundreds of stacks can be deployed by customers. These will be countries, infrastructure investors, foodservice operators, farmers, and land-developers with temporarily-unused properties. Mart Salumäe, CEO of Decomer Technologies (decomertechnology.com) Plastics pollution is an exploding issue for CPG brands as the environmental impacts of products designed to be used for minutes but last for lifetimes is seen. Rather than attempt to change mass-market consumer behavior, industry is challenged to think green while maintaining convenience. To solve this, Decomer Technology has developed a new sustainable packaging material that is edible and rapidly dissolves in liquids. It has widespread uses across the food industry, pharmaceuticals, agriculture, and detergents. Their material is odorless, tasteless, and hypoallergenic, though flavors and micronutrients can be added. It can be tuned to dissolve in cold water, or hot water, or both. It’s very low cost and scalable for high volume manufacturing uses. Matt Gibson, CEO of New Culture (newculture.co.nz) New Culture is making cheese without the cow. Combining dairy proteins, expressed by microflora, with plant lipids and sugars, their method arrives at curds that are then advanced into the traditional cheesemaking process, be that stirred, kneaded, stretched or aged. New Culture’s cheese has the signature textural properties and qualities that we’re all familiar with in dairy cheese.
- Harnessing the Microbiome for Human and Plant Health
*** RSVP on Eventbrite: https://www.eventbrite.com/e/harnessing-the-microbiome-for-human-and-plant-health-tickets-58033741483 *** The microbes living on us and in our environment are constantly in balance to keep us healthy. We are only beginning to understand these mechanisms and trying to harness their power to fight disease. But what is the perfect microbiome? How does it vary between individuals? And can microbiome interventions cure disease? Join us in discussing how startups are helping to find these answers, the challenges they face, and the possibilities for the future of health. Food and drinks provided. Speakers: Dr. Elisabeth Bik, Founder of Microbiome Digest (https://microbiomedigest.com/) Elisabeth is the founder of Microbiome Digest, a daily compilation of scientific papers in the microbiome since 2014. She has a PhD in microbiology and was former Scientific Editorial Director at uBiome and a microbiome consultant. Dr. Siv Watkins, CEO of 11Biomics (https://www.11biomics.com/) Powdery mildew disease can spike in a cannabis grow operation overnight, ruining a harvest worth millions. 11Biomics has developed non-chemical plant therapeutics for powdery mildew and other plant diseases. Kevin Honaker, CEO of BiomeSense (http://biomesenseinc.com) The microbiome is one of the most impactful emerging fields in healthcare, yet fundamentally constrained by an inability to collect longitudonal patient data. BiomeSense is developing a platform for daily collection, storage, and analysis of patient microbiome profiles. PR Yu, Managing Partner of SV Tech Ventures (http://www.svtechsummit.com/) SV Tech Ventures is a very active early stage investor and has invested in a microbiome startup. *** RSVP on Eventbrite: https://www.eventbrite.com/e/harnessing-the-microbiome-for-human-and-plant-health-tickets-58033741483 ***